← Back to Search

Active SMS Group for High Blood Pressure (DREAM-GLOBAL Trial)

N/A
Waitlist Available
Led By Norman RC Campbell, MD, FRCPC
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year
Awards & highlights
No Placebo-Only Group

Summary

Heart disease and stroke are the number one killers world-wide. When someone has hypertension, the constantly elevated blood pressure damages their blood vessels and the organs that they supply blood to. This causes stroke, heart attack, heart failure, kidney failure and dementia. Finding and lowering high blood pressure to normal with lifestyle changes and if necessary medications, lowers the risk of these outcomes. Canada has high rates of blood pressure control compared to other countries in the world, due in large part to the successful dissemination of hypertension guidelines. However remote and disadvantaged communities have not been as successful and need additional measures to help achieve the same level of blood pressure control as the rest of the country. The DREAM-GLOBAL team has extensive experience working with Canada's Aboriginal Communities and a large community in Tanzania. The DREAM-GLOBAL project will integrate innovations in technology with the implementation of guidelines-based blood pressure control and through partnerships with experts in government and industry, overcome barriers to lowering blood pressure in Canada's Aboriginal Communities, and in a community in Tanzania. Tools will be developed and tested that will close the circle of care around people with hypertension by bringing measurement data to the medical record and health care provider and also sending useful medical feedback to the person with hypertension via secure data servers and routine SMS messaging on cell phones. The system will be tested for effectiveness of diagnosing and also for managing hypertension. To begin the process of preventing hypertension, the team will also explore with an Aboriginal community how to create policies to reduce the sodium content in their food. If proven effective, DREAM-GLOBAL can also become a platform for managing other chronic diseases.

Eligible Conditions
  • High Blood Pressure
  • Diabetes
  • Cardiovascular Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Blood Pressure

Side effects data

From 2019 Phase 4 trial • 35 Patients • NCT02420015
14%
Sleep problems and/or nightmares
14%
Suicidal ideation
14%
Mouth and/or throat irritation
10%
Skin irritation
10%
Nausea, upset stomach
10%
Jitteriness, shakiness
10%
Family violence
10%
Flu
10%
Hospitalization
5%
Dental surgery
5%
Increased seizures
5%
Pain
5%
Increased psychiatric symptoms
5%
dizziness
5%
Car accident
5%
Increased foot pain
5%
Sweating
5%
Asthma
5%
Benign tumor removed from lung
100%
80%
60%
40%
20%
0%
Study treatment Arm
iCOMMIT
Control Group

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Active SMS GroupExperimental Treatment1 Intervention
Active SMS messages based on hypertension clinical practice guidelines including rational for taking antihypertensive medication and reminders to see the health care practioner if BP is above target.
Group II: Passive SMS GroupActive Control1 Intervention
Passive SMS messages focused on lifestyle adjustment

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
674 Previous Clinical Trials
1,565,495 Total Patients Enrolled
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,387 Previous Clinical Trials
26,515,713 Total Patients Enrolled
Norman RC Campbell, MD, FRCPCPrincipal InvestigatorUniversity of Calgary
~26 spots leftby Nov 2025